Clara van Karnebeek
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Leigh syndrome (LS) is a devastating mitochondrial disease (MD) for which there is no treatment. Together with Leigh-like syndrome (LLS), LS constitutes part of the Leigh syndrome spectrum (LSS) disorders, which are the most frequent manifestation of a primary mitochondrial disease (MD) in children. Ndufs4 -/- mice are a widely used animal model to study LS pathophysiology and interventions. These mice display an isolated mitochondrial complex I deficiency and a brain-specific pathomechanism. Similar to other mouse models of human disease, Ndufs4 -/- mice are routinely housed and studied at a sub-thermoneutral ambient temperature. This means that these mice experience chronic cold-stress, which potentially aggravates disease symptoms and reduces their translational value. Here, we provide evidence that housing Ndufs4 -/- mice at 26 °C instead of 20 °C increases their skin, core and brain temperature. At this higher temperature, Ndufs4 -/- mice displayed lower energy expenditure and, importantly, a longer lifespan, pathology reversal in specific brain regions, as well as increased voluntary locomotor activity. We conclude that ambient temperature is a previously overlooked but highly relevant disease modifier in Ndufs4 -/- mice. Given the reduced mitochondrial energy production and aberrant thermoregulation in LSS and other MD patients, our findings suggest that reducing energy requirements might be of therapeutic value and/or contribute to an improved quality of life in these patients. In a broader sense, our results advocate the use of (more) thermoneutral housing to evaluate pathomechanisms and intervention strategies in murine models of human disease. Significance We conclude that ambient temperature is a previously overlooked but highly relevant disease modifier in Ndufs4 -/- mice. Given the reduced mitochondrial energy production and aberrant thermoregulation in LS and other MD patients, our findings suggest that reducing energy requirements might be of therapeutic value and/or contribute to an improved quality of life in these patients. In a broader sense, our results clearly demonstrate why it is essential to use a (more) thermoneutral housing to evaluate pathomechanisms and intervention strategies in translational research with murine models of human disease.
Year:
2025
OSMRβ (Oncostatin M receptor beta), a member of the IL-6 superfamily of cell surface receptors, binds OSM and IL-31 and plays a critical role in human immunity. We identified probands from four kindreds with biallelic damaging variants in OSMR , which encodes OSMRβ. Patients had a unifying phenotype for severe widespread, early-onset atopic dermatitis, peripheral eosinophilia, and elevated serum IgE. Patient OSMRβ variants were not appropriately expressed on the cell surface compared to OSMRβ WT . Patient OSMR variants showed significantly reduced OSM-mediated activation of STAT1, STAT3, and STAT5 and distinct transcriptional changes in primary dermal fibroblasts, including loss of interferon and inflammatory signatures. These defects were rescued upon lentiviral transduction of WT- OSMR . Together, these data establish that human germline biallelic loss-of-function OSMR variants cause severe allergic disease. We anticipate that this discovery will facilitate the recognition of additional affected individuals and the full definition of this novel primary atopic disorder.
Year:
2025
Pyridoxine-dependent epilepsy (PDE) is a rare neurometabolic disorder of lysine catabolism caused by bi-allelic variants in ALDH7A1 . This enzyme deficiency leads to the accumulation of neurotoxic metabolites, pyridoxal-phosphate inactivation and consequently severe neurological symptoms. Current treatments, including vitamin B6 supplementation and lysine-restricted diets, partially alleviate seizures and intellectual disability but are not curative. To explore underlying mechanisms and potential therapies, we generated patient-derived human induced pluripotent stem lines (hiPSC) that were subsequently differentiated into astrocytes, the primary source of ALDH7A1 in the brain and key regulators of metabolic homeostasis. Metabolomic analyses confirmed elevated PDE biomarkers, and RNA sequencing revealed gene expression changes consistent with increased oxidative stress. Oxidative damage was validated by markers of DNA oxidation and lipid peroxidation. In addition, dysregulated oxygen consumption rates suggested mitochondrial dysfunction in PDE astrocytes. Notably, these pathological phenotypes were alleviated by downregulating AASS , the first enzyme of the lysine catabolism, by using CRISPR/Cas9 editing or antisense oligonucleotides (AON). This demonstrates that lysine catabolism underlies these phenotypes and highlights the therapeutic potential of AON therapy targeting AASS to reduce neurotoxic metabolite accumulation. These findings provide a promising strategy for developing targeted treatments for PDE and other rare neurometabolic disorders.
Year:
2025
Background Trinucleotide repeat expansions are an emerging class of genetic variants associated with several movement disorders. Unbiased genome-wide analyses can reveal novel genotype-phenotype associations and provide a diagnosis for patients and families. Objectives To identify the genetic cause of a severe progressive movement disorder phenotype in two affected brothers. Methods A family of two affected brothers and unaffected parents had extensive phenotyping and natural history followed since birth. Whole-genome and long-read sequencing methods were used to characterize genetic variants and methylation status. Results: We describe a CGG repeat expansion in the 5’-untranslated region of DIP2B in two affected male siblings presenting with a novel DIP2B phenotype including neurodevelopmental disability, dysmorphic traits, and a severe progressive movement disorder (prominent chorea, dystonia, and ataxia). Conclusions This is the first report of a severe progressive movement disorder phenotype attributed to a CGG repeat expansion in the DIP2B 5’-UTR.
Year:
2024
Collaborators (23)
PHILLIP RICHMOND
Research Associate Professor
University of Colorado Boulder
Dirk J. Lefeber
professor Glycosylation Disorders in Neurology
Radboud University Medical Center
Stuart Turvey
Professor
The University of British Columbia
Werner J.H. Koopman
Associate professor
Radboud University Medical Center
Jaap Keijer
Full professor in Human and Animal Physiology and chair
Wageningen University & Research
Geraldine Blanchard-Rohner
University Hospital of Geneva
Pascal M Lavoie
The University of British Columbia
massimo mangino
Honorary Senior Lecturer
King’s College London
Ashish Arunkumar Sharma
Assistant Professor
Emory University
Heikki Koistinen
University of Helsinki
Britt I. Drögemöller
Assistant Professor
University of Manitoba
Colin Ross
Professor
The University of British Columbia
Alex Garanto
Associate Professor / Research Group Leader
Radboudumc
Wyeth Wasserman
Professor
The University of British Columbia
Blair Leavitt
Professor
The University of British Columbia
Gabriella Horvath
Clinical Professor
The University of British Columbia
Evert van Schothorst
Wageningen University & Research
Maja Tarailo-Graovac
Associate Professor
University of Calgary
Wingfield Rehmus
The University of British Columbia
Michael Boehnke
Professor
University of Michigan
Judith Homberg
Assoc. Professor
Radboud Universiteit Donders Institute for Brain Cognition and Behaviour
Jonathan Lyons
Professor of Medicine
University of California, San Diego
Nael Nadif Kasri
Full professor
Radboudumc
Make your next move.
Prepare your application
Review drafts before you send them.